{"id":76210,"date":"2026-09-11T06:21:00","date_gmt":"2026-09-11T04:21:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/complement-inhibition-in-pediatric-anca-associated-vasculitis\/"},"modified":"2026-09-11T06:21:00","modified_gmt":"2026-09-11T04:21:00","slug":"complement-inhibition-in-pediatric-anca-associated-vasculitis","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/complement-inhibition-in-pediatric-anca-associated-vasculitis\/","title":{"rendered":"Complement inhibition in pediatric ANCA-associated vasculitis"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2026 Sep 10;103:102839. doi: 10.1016\/j.coi.2026.102839. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in childhood is a rare but severe condition associated with significant morbidity and treatment-related toxicity. Current therapies mainly rely on high-dose glucocorticoids and conventional immunosuppressants, which may cause substantial long-term adverse effects in pediatric patients. Advances in the understanding of AAV pathogenesis have identified the alternative complement pathway, particularly the C5a-C5a receptor axis, as a key driver of inflammation and vascular injury, leading to the development of complement-targeting therapies. While these agents have shown efficacy and steroid-sparing effects in adults, pediatric evidence remains limited to case reports and small case series. Available data suggest that complement inhibitors may represent a promising option for selected children with refractory disease, although concerns remain regarding dosing, long-term safety, and accessibility. This review summarizes current evidence, discusses unmet clinical needs, and highlights the need for collaborative pediatric studies and dedicated clinical trials.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42721938\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20260911002059&amp;v=2.20.1\">42721938<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2026.102839\">10.1016\/j.coi.2026.102839<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2026 Sep 10;103:102839. doi: 10.1016\/j.coi.2026.102839. Online ahead of print. ABSTRACT Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in childhood is a rare but severe condition associated with significant morbidity and treatment-related toxicity. Current therapies mainly rely on high-dose glucocorticoids and conventional immunosuppressants, which may cause substantial long-term adverse effects in pediatric patients. Advances &#8230; <a title=\"Complement inhibition in pediatric ANCA-associated vasculitis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/complement-inhibition-in-pediatric-anca-associated-vasculitis\/\" aria-label=\"Read more about Complement inhibition in pediatric ANCA-associated vasculitis\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-76210","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=76210"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76210\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=76210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=76210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=76210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}